Logo

American Heart Association

  15
  0


Final ID: MP2076

Potential Patient Eligibility for Hospital at Home for Management of Worsening Heart Failure in the United States

Abstract Body (Do not enter title and authors here): Introduction/Background
Hospital at Home (HaH) is an emerging, patient-centered clinical model by which patients receive inpatient-level care at home. HaH may be particularly well-suited to the care of patients with worsening heart failure (WHF).
Research Questions
Our study sought to examine, if implemented widely, what proportion of US patients hospitalized with WHF would be eligible for HaH care. We also sought to determine the clinical and demographic differences between HaH eligible and ineligible populations.
Methods/Approach
Among US patients hospitalized for WHF in the Get With The Guidelines – Heart Failure (GWTG-HF) registry from 2021-2024, we applied generally accepted and/or required (by Medicare) social and clinical criteria for HaH to estimate the proportion of patients potentially eligible for HaH. We then further compared the demographics, vital signs and laboratory findings, comorbidities, mortality, and length of stay for the HaH eligible and ineligible groups.
Results/Data
Among 81,610 patients hospitalized across 204 sites, 49,544 (60.7%) were projected as eligible for HaH (Table 1). Eligibility rates were >50% across demographic and geographic subgroups but tended to be higher among patients age >75 years, women, and Hispanic patients, as well as among patients hospitalized in urban areas and the Northeast US (Figure). Eligible patients were less likely to have a history of chronic kidney disease and had a lower median GWTG-HF risk score (Table 2). Patients eligible for HaH had lower in-hospital mortality and shorter length of stay (Table 2).
Conclusions
In this nationwide cohort of US patients hospitalized for WHF, approximately 6 out of 10 patients were projected as potentially eligible for HaH, with modest variability across demographic and geographic subgroups. Patients eligible for HaH demonstrated a lower risk clinical profile. HaH could conceivably be a viable treatment strategy for the majority of US patients with WHF, and national efforts to continue or expand HaH have the potential to substantially impact WHF care delivery.
  • Haywood, Hubert  ( Duke University Hospital , Durham , North Carolina , United States )
  • Ayodele, Iyanuoluwa  ( DCRI , Jonesboro , Georgia , United States )
  • Fonarow, Gregg  ( UCLA MEDICAL CENTER , Los Angeles , California , United States )
  • Alhanti, Brooke  ( Duke University , Durham , North Carolina , United States )
  • Van Spall, Harriette  ( McMaster University , Hamilton , Ontario , Canada )
  • Pandey, Ambarish  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Lewsey, Sabra  ( Johns Hopkins University , Baltimore , Maryland , United States )
  • Butler, Javed  ( Baylor Scott and White Research , Dallas , Texas , United States )
  • Greene, Stephen  ( Duke Clinical Research Institute , Durham , North Carolina , United States )
  • Author Disclosures:
    Hubert Haywood: DO NOT have relevant financial relationships | Iyanuoluwa Ayodele: No Answer | Gregg Fonarow: DO have relevant financial relationships ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Consultant:Pfizer:Active (exists now) ; Consultant:Merck:Active (exists now) | Brooke Alhanti: DO NOT have relevant financial relationships | Harriette Van Spall: DO have relevant financial relationships ; Consultant:Astra Zeneca:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Roche:Active (exists now) ; Other (please indicate in the box next to the company name):Novartis - Educational Account:Past (completed) ; Consultant:Medtronic:Active (exists now) ; Other (please indicate in the box next to the company name):Medtronic - Clinical Trial Executive Committee Role:Active (exists now) ; Research Funding (PI or named investigator):Heart and Stroke Foundation of Canada:Past (completed) ; Other (please indicate in the box next to the company name):Colorado Prevention Center Clinical Research - Clinical Trial Executive Committee Role:Active (exists now) ; Other (please indicate in the box next to the company name):CardioVascular Research Foundation - Clinical Trial Events Committee:Active (exists now) ; Research Funding (PI or named investigator):Canadian Institutes of Health Research:Active (exists now) ; Other (please indicate in the box next to the company name):Boehringer Ingelheim Pharmaceuticals, Inc - Educational Account:Past (completed) ; Consultant:Bayer:Active (exists now) ; Other (please indicate in the box next to the company name):Bayer - Advisory Board:Active (exists now) ; Consultant:Baim Institute for Clinical Research:Active (exists now) | Ambarish Pandey: DO have relevant financial relationships ; Consultant:Tricog:Active (exists now) ; Consultant:Sarfez Therapeutics, Edwards Lifesciences, Merck, Bayer, Anumana, Alleviant, Pfizer, Abbott, Axon Therapies, Kilele Health, Acorai, Kardigan, Novartis, Idorsia Pharma, and Science37:Active (exists now) ; Consultant:Rivus:Active (exists now) ; Consultant:iRhythm:Active (exists now) ; Researcher:SQ innovations:Active (exists now) ; Research Funding (PI or named investigator):SC Pharma:Active (exists now) ; Consultant:Astra Zeneca:Active (exists now) ; Research Funding (PI or named investigator):Ultromics:Active (exists now) ; Research Funding (PI or named investigator):Roche:Active (exists now) ; Consultant:Ultromics:Active (exists now) ; Consultant:Roche:Active (exists now) ; Consultant:Lilly:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) | Sabra Lewsey: DO NOT have relevant financial relationships | Javed Butler: DO have relevant financial relationships ; Consultant:Abbott :Active (exists now) ; Consultant:Daxor, Diastol, Edwards, Element Sciences, Faraday, Idorsia, Impulse Dynamics, Imbria, Innolife, Intellia, Inventiva, Levator, Lexicon, Eli Lilly, Mankind, Medtronic, Merck, New Amsterdam, Novartis, NovoNordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Pulnovo, Regeneron, Renibus, Reprieve, Roche, Rycarma, Saillent, Salamandra, Salubris, SC Pharma, SQ Innovation, Secretome, Sequanna, Transmural, TekkunLev, Tenex, Tricog, Ultromic, Vera, Zoll:Active (exists now) ; Consultant:Cytokinetics:Active (exists now) ; Consultant:CVRx:Active (exists now) ; Consultant:CSL Vifor:Active (exists now) ; Consultant:Cardior:Active (exists now) ; Consultant:Cardiac Dimension:Active (exists now) ; Consultant:Bristol Myers Squibb:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:AskBio:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Consultant:American Regent:Active (exists now) ; Consultant:Adaptyx:Active (exists now) | Stephen Greene: DO have relevant financial relationships ; Consultant:Amgen:Active (exists now) ; Consultant:Tricog Health:Active (exists now) ; Consultant:Otsuka:Active (exists now) ; Researcher:Novartis:Active (exists now) ; Consultant:Sumitomo:Active (exists now) ; Consultant:Lexicon:Active (exists now) ; Advisor:Lilly:Active (exists now) ; Advisor:Novo Nordisk:Active (exists now) ; Consultant:Roche Diagnostics:Active (exists now) ; Consultant:Merck:Active (exists now) ; Advisor:Corcept:Active (exists now) ; Consultant:CSL Vifor:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:AstraZeneca:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

From Molecules to Mindsets: Multidimensional Perspectives on Heart Failure

Monday, 11/10/2025 , 12:15PM - 01:00PM

Moderated Digital Poster Session

More abstracts on this topic:
More abstracts from these authors:
Social Determinants of Health and Disparities in Guideline-Directed Medical Therapy Optimization for Heart Failure

Jacobs Joshua, Alhanti Brooke, Blanco Rosalia, Fonarow Gregg, Ayodele Iyanuoluwa, Bress Adam, Sterling Madeline, Pandey Ambarish, Derington Catherine, Zheutlin Alexander, Shah Kevin, Greene Stephen

Post-Discharge Outcomes and Healthcare Costs for Patients Hospitalized for Heart Failure with Transthyretin Amyloid Cardiomyopathy: Findings From GWTG–HF

Shoji Satoshi, Wright Jason, Vaduganathan Muthiah, Greene Stephen, Ikeaba Uchechukwu, Fonarow Gregg, Selvaraj Senthil, Lewsey Sabra, Pandey Ambarish, Khouri Michel, Alhanti Brooke, Mcdermott Jim

You have to be authorized to contact abstract author. Please, Login
Not Available